IP Verse

Eisai R&d Management competitive analysis

Latest publications and patents of Eisai R&d Management New

Explore the latest publications and patents granted to Eisai R&d Management, showcasing their recent innovations and technological advancements.

Last updated on: Sep 29, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Eisai R&d Management

EP3581183
Nov 29, 2023Tumor-Treating Pharmaceutical CompositionGranted And Under Opposition
EP3263106
Oct 25, 2023Method For Suppressing Bitterness Of Quinoline DerivativeGranted And Under Opposition
EP3524595
Aug 10, 2022High-Purity Quinoline Derivative And Method For Manufacturing SameGranted And Under Opposition
EP3265122
May 4, 2022Combination Of A Pd-1 Antagonist And Eribulin For Treating CancerRevoked
EP3338779
Jun 30, 2021Tumor Therapeutic AgentGranted And Under Opposition
EP2452684
Jan 24, 2018MicellesNo Opposition Filed Within Time Limit

Latest patents of Eisai R&d Management opposed by its competitors

Explore Eisai R&d Management's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3581183
Nov 29, 2023Tumor-Treating Pharmaceutical Composition1
EP3263106
Oct 25, 2023Method For Suppressing Bitterness Of Quinoline Derivative8
EP3524595
Aug 10, 2022High-Purity Quinoline Derivative And Method For Manufacturing Same9
EP3265122
May 4, 2022Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer4
EP3338779
Jun 30, 2021Tumor Therapeutic Agent1

Latest PTAB cases involving Eisai R&d Management

Discover the latest PTAB cases involving Eisai R&d Management, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Eisai R&d Management with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
EISAI R&D MANAGEMENT - 23 - - Non-Active
ACCORD HEALTHCARE34 - 4 - Highly Aggressive
GENERICS UK212 - - - Highly Aggressive
STADA ARZNEIMITTEL10828 - - Highly Aggressive